Active NOTCH signaling has been linked, in different types of cancer, to resistance towards a broad range of chemotherapeutics and targeted agents, reviewed by Takebe et al. (16), including cisplatin (17), docetaxel (18), paclitaxel (19), gefitinib (20), anti-HER2 (human epidermal growth factor receptor 2) (21), anti-estrogens (22), dasatinib (23), temozolomide (24), doxorubicin and melphalan (25). The gene discussed is ERBB2; the disease is cancer.